Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr;15(2):237-248.
doi: 10.1007/s40258-016-0301-y.

Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden

Åsa Ericsson  1 , Adam Lundqvist  2
Affiliations

Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden

Åsa Ericsson et al. Appl Health Econ Health Policy. 2017 Apr.

Abstract

Background: Patients with uncontrolled type 2 diabetes mellitus (T2DM) are a priority group for intensified therapy without weight gain and with low risk of hypoglycaemia.

Objective: This study evaluates the cost effectiveness of insulin degludec plus liraglutide (IDegLira, Xultophy®) compared with six potential intensification treatment options for patients with T2DM that is uncontrolled with basal insulin.

Methods: The Swedish Institute for Health Economics (IHE) Cohort Model of Type 2 Diabetes was used with Swedish input data, a 40-year time frame and a societal perspective. The comparators for treatment intensification included insulin glargine, neutral protamine Hagedorn (NPH) insulin, insulin aspart plus either glargine or NPH, and liraglutide plus either glargine or NPH. Clinical data for all comparators (except NPH insulin) were based on an indirect treatment comparison of several studies. Prices were obtained from the 2014 Swedish Dental and Pharmaceutical Benefits Agency (Tandvårds- och läkemedelsförmånsverket [TLV]) database, and utility values were obtained from published studies. Sensitivity analyses were undertaken.

Results: Overall incremental cost-effectiveness ratios (ICER) were Swedish krona (SEK) 70,000 or lower per quality-adjusted life-year (QALY). IDegLira compared with intensified basal insulin showed an ICER of SEK 28,000 per QALY versus insulin glargine, SEK70,000 per QALY versus NPH insulin and SEK 60,000 per QALY versus NPH insulin plus liraglutide. IDegLira was dominant over insulin glargine plus liraglutide and insulin aspart plus insulin glargine or NPH insulin. Results were driven by the difference in glycated haemoglobin (HbA1c) reduction between treatments, as confirmed by sensitivity analyses.

Conclusions: IDegLira is estimated to be a cost-effective treatment in Sweden compared with commonly used intensification treatments for patients with T2DM uncontrolled with basal insulin.

PubMed Disclaimer

Conflict of interest statement

Funding

This study was funded by Novo Nordisk Scandinavia AB, the manufacturer of IDegLira.

Conflict of interest

Åsa Ericsson is an employee of Novo Nordisk Scandinavia AB. Adam Lundqvist is an employee at IHE and declares no conflicts of interest.

References

    1. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–412. doi: 10.1136/bmj.321.7258.405. - DOI - PMC - PubMed
    1. American Diabetes Association Standards of medical care in diabetes: 2008. Diabetes Care. 2008;31(Suppl 1):S12–S54. doi: 10.2337/dc08-S012. - DOI - PubMed
    1. Socialstyrelsen. Nationella riktlinjer för diabetesvården 2010 – Stöd för styrning och ledning 2010. http://www.socialstyrelsen.se/. Accessed 22 Dec 2016.
    1. International Diabetes Federation. Global guideline for type 2 diabetes 2012. https://www.idf.org/global-guideline-type-2-diabetes-2012. Accessed 22 Dec 2016.
    1. National Diabetes Register. NDR Statistik. https://ndrstatistik.registercentrum.se/ . Accessed 22 Dec 2016.

MeSH terms